Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01898715
Recruitment Status : Completed
First Posted : July 12, 2013
Last Update Posted : November 6, 2017
Information provided by (Responsible Party):
Millendo Therapeutics, Inc.

Brief Summary:
This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy. Information will also be collected to determine how long ATR-101 stays in the blood, and if any effect on tumor progression is seen. Biomarkers (blood and urine tests) will determine if any effects on production of steroid hormones (cortisol, aldosterone, estrogen and testosterone) are seen.

Condition or disease Intervention/treatment Phase
Adrenocortical Carcinoma Adrenal Cancer ACC Drug: ATR-101 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
Actual Study Start Date : August 13, 2013
Actual Primary Completion Date : November 2, 2016
Actual Study Completion Date : October 17, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ATR-101
ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
Drug: ATR-101

Primary Outcome Measures :
  1. Frequency of dose-limiting toxicity and determination of maximum tolerated dose [ Time Frame: Occurrence of DLT at 28 days ]
    Adverse events will be recorded and tabulated by grade and system organ class according to CTCAE v 4.03. Laboratory measures and ECGs will be assessed.

Secondary Outcome Measures :
  1. Area under the plasma concentration versus time curve (AUC) of ATR-101 [ Time Frame: Day 1 and Day 22 ]
    Plasma levels of ATR-101 will be assessed after daily oral dosing and pharmacokinetic parameters will be calculated.

  2. Change in plasma cortisol levels [ Time Frame: Baseline and day 22 ]
  3. Change in objective measurement of tumor size [ Time Frame: Baseline and 8 weeks ]
    CT or MRI scans will be read according to RECIST 1.1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

18 years;

  • Clinical confirmation of adrenocortical carcinoma that is locally advanced or metastatic and not amendable to surgical resection;
  • Failed or declined mitotane (adjuvant or therapeutic) therapy or a platinum-based chemotherapy regimen;
  • Able to understand and comply with the protocol requirements;
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • Mitotane level > 5
  • Use of contraindicated concomitant medications
  • Unstable medical condition that, in the judgment of the investigator, could interfere with study procedures or data interpretation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01898715

Layout table for location information
United States, Florida
Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Maryland
National Institutes of Health/National Cancer Institute
Bethesda, Maryland, United States, 20892
United States, Michigan
University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48103
United States, Texas
MDAnderson Cancer Center
Houston, Texas, United States, 77030
Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg
Würzburg, Germany
Sponsors and Collaborators
Millendo Therapeutics, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Millendo Therapeutics, Inc. Identifier: NCT01898715    
Other Study ID Numbers: ATR-101-001
First Posted: July 12, 2013    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: November 2017
Keywords provided by Millendo Therapeutics, Inc.:
Adrenocortical carcinoma
Adrenal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenocortical Carcinoma
Adrenal Gland Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Adrenal Cortex Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Adrenal Cortex Diseases
Adrenal Gland Diseases
Endocrine System Diseases